Act as the translational medicine lead for assigned early Oncology programs (preclinical to Phase 1)
Define and own biomarker and translational strategies, plans and decision-enabling datasets
Identify cutting edge science and technological advances and incorporate them into biomarker strategies
Develop program-specific translational plans including hypothesis-driven biomarker selection, assay strategy (fit-for-purpose), sample collection/handling, and statistical/analysis plans
Provide critical scientific input into target validation and discovery phases, pharmacology, PK/PD, target engagement, mechanism-of-action and patient selection strategies across modalities
Lead assay selection, qualification/validation strategy and oversight (internal and external CROs/diagnostic partners)
Integrate preclinical model data with clinical development plans
Serve as the primary cross-functional interface for translational questions

PhD and/or MD with substantive experience in Oncology
Minimum 5 years of experience in translational medicine, biomarker science, clinical development and particularly the application of biomarkers strategies in Oncology clinical trials
Expertise in cancer biology across key disease areas of focus with an emphasis on haematological cancers (multiple myeloma)
Demonstrated expertise across multiple therapeutic modalities relevant to the GSK portfolio: large molecules, small molecules and immune cell engagers
Proven track record of designing and executing translational biomarker strategies in early
and late-phase clinical trials, including assay development, validation, and clinical deployment
Hands-on experience of implementation of a range of biomarker platforms including flow cytometry, molecular diagnostics (NGS, FISH, PCR), and/or IHC/IF for Oncology clinical trials

Director, Senior Director – Oncology Early Translational Biomarkers (Haematological Cancer)

About this role